Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00227773
Other study ID # CDR0000446076
Secondary ID ECOG-E6203
Status Withdrawn
Phase Phase 2
First received September 26, 2005
Last updated October 6, 2015

Study information

Verified date October 2015
Source Eastern Cooperative Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide may be an effective treatment for neuroendocrine tumors.

PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide works in treating patients with progressive neuroendocrine tumors.


Description:

OBJECTIVES:

- Determine the 4-month progression-free and overall survival of patients with progressive low-grade neuroendocrine tumors treated with vatalanib and octreotide.

- Determine the response rate in patients treated with this regimen.

- Determine the effect of this regimen on tumor markers (e.g., chromogranin A, 5-HIAA, and gastrin) in these patients.

- Determine the toxicity and tolerability of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive oral vatalanib once daily on days 1- 28 and octreotide* intramuscularly or IV on day 1. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

NOTE: *Patients on a stable dose (i.e., no changes in dosage within the past 3 months) of octreotide before study entry remain on their current dose and schedule during study participation; patients who experience hypersensitivity and/or toxicity to octreotide may receive vatalanib alone.

After completion of study treatment, patients are followed at 4 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 3 years.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 120 Years
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed low-grade neuroendocrine tumors

- The following tumor types are excluded:

- Small cell lung cancer

- Medullary thyroid cancer

- Paraganglioma

- Pheochromocytoma

- Measurable disease

- Radiographic evidence of disease progression after completion of any prior systemic therapy, chemoembolization, bland embolization, or observation within the past year, defined as either of the following:

- Appearance of a new lesion

- At least 20% increase in the longest diameter (LD) of any previously documented lesion or an increase in the sum of the LDs of multiple lesions in the aggregate of 20%

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-2

Life expectancy

- Not specified

Hematopoietic

- Absolute neutrophil count = 1,000/mm^3

- Platelet count = 75,000/mm^3

- Hemoglobin = 8.0 g/dL

Hepatic

- Bilirubin = 2.0 times upper limit of normal (ULN)

- AST = 3 times ULN (5 times ULN if liver metastases are present)

Renal

- Creatinine = 1.5 times ULN

- Meets 1 of the following criteria:

- Urine protein negative by dipstick

- Urine protein:creatinine ratio < 1.0

- Urine protein < 1 g by 24-hour urine collection

Gastrointestinal

- Must be able to swallow tablets

- No ulcerative disease

- No uncontrolled nausea, vomiting, or diarrhea

- No bowel obstruction

- No other gastrointestinal tract disease resulting in an inability to take oral medication

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Must be able to receive a contrast-enhanced CT scan

- No known history of allergic reaction to vatalanib or its derivatives or octreotide injections

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- At least 4 weeks since prior chemotherapy

- No more than 1 prior systemic chemotherapy regimen

- Chemoembolization is not considered systemic chemotherapy

- No concurrent chemotherapy

Endocrine therapy

- Not specified

Radiotherapy

- At least 3 weeks since prior radiotherapy

- No concurrent radiotherapy

Surgery

- At least 4 weeks since prior major surgery

Other

- At least 4 weeks since other prior systemic therapy

- At least 4 weeks since prior local liver therapy

- No prior anti-vascular endothelial growth factor agents

- No concurrent grapefruit or grapefruit juice

- No concurrent therapeutic warfarin or similar oral anticoagulants that are metabolized by the cytochrome P450 system

- Concurrent heparin allowed

Study Design

Primary Purpose: Treatment


Intervention

Drug:
octreotide acetate

vatalanib

Procedure:
anti-cytokine therapy

antiangiogenesis therapy

biological therapy

endocrine therapy

enzyme inhibitor therapy

growth factor antagonist therapy

hormone therapy

protein tyrosine kinase inhibitor therapy

somatostatin analogue therapy


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Eastern Cooperative Oncology Group National Cancer Institute (NCI)
See also
  Status Clinical Trial Phase
Completed NCT01048892 - Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Phase 1
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1
Completed NCT00002470 - Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Phase 2
Active, not recruiting NCT00454376 - Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Phase 4
Terminated NCT00002947 - Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Phase 1
Completed NCT00427349 - AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Phase 2
Completed NCT00416767 - Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Phase 2
Completed NCT00005049 - Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Phase 2
Completed NCT00027638 - Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00019474 - Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Phase 2
Terminated NCT00227617 - Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Phase 2/Phase 3
Completed NCT00654160 - Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Phase 1
Completed NCT00049023 - Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors Phase 1
Completed NCT00004911 - Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Phase 1/Phase 2
Completed NCT00004910 - Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Phase 1/Phase 2
Completed NCT00006368 - Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Phase 1
Active, not recruiting NCT00730483 - Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors N/A
Completed NCT00602082 - Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Phase 2
Completed NCT00017199 - PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Phase 2